/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
With a market cap of $115.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a leading biotechnology firm based in Boston, best known for its dominance in cystic fibrosis treatments through drugs like Trikafta.
Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Vertex Pharmaceuticals fits this criterion perfectly. Its market dominance, innovative pipeline, and financial resilience make it a leading player in the biotechnology industry. The company is also a pioneer in advanced therapies, including gene-editing (Casgevy) and non-opioid pain management (JOURNAVX).